The Hidden Flaw in Living Drugs and the New Standard to Fix It

CHARLOTTESVILLE, VA – June 02, 2026 – The frontier of modern medicine is not a pill; it is a living cell, reprogrammed and redeployed to fight our most intractable diseases. From cancer to genetic disorders, cell and gene therapies represent a paradigm shift in treatment. Yet, behind the triumphant headlines lies a systemic vulnerability, a gap between the promise of these revolutionary treatments and the reality of their complex manufacturing. For decades, the industry has relied on a surprisingly crude method to answer the most basic question: are the cells we are about to put into a patient truly healthy? Now, a new global standard aims to finally close that gap, bringing 21st-century accountability to the delicate art of cultivating living drugs.

The Problem with 'Good Enough'

At the heart of nearly every cell therapy process is a deceptively simple step: a viability check. For generations of scientists, this has meant using a method called trypan blue exclusion. The concept is straightforward: the blue dye can only enter cells with a ruptured membrane, staining dead cells while leaving live ones clear. It is cheap, fast, and has been the workhorse of biology labs for nearly a century.

But in the high-stakes world of advanced therapy manufacturing, this method’s simplicity is its critical flaw. Trypan blue can only identify a cell that is already dead. It is blind to the vast and crucial grey area of cells that are functionally compromised, stressed, or in the early stages of apoptosis—a programmed cell death. These cells, while still having an intact membrane, are essentially zombies: technically alive but incapable of performing their therapeutic function and potentially detrimental to the manufacturing process.

“You can have a culture that scores a 95% viability with trypan blue, but in reality, a significant portion of those cells are already on a path to dying,” explained one industry consultant, who spoke on the condition of anonymity. “That introduces massive, unpredictable variability. It affects your process, your yield, and ultimately, it could affect the potency of the final dose a patient receives.” This variability has been a persistent bottleneck, impacting everything from lot release decisions to the transfer of manufacturing technology between sites, slowing the progress of life-saving treatments.

A New Global Rulebook for Cells

Addressing this foundational challenge is the newly published International Organization for Standardization (ISO) global standard, ISO 8934-1:2026: Biotechnology — Cell viability analytical methods. Developed through a consensus-based process by ISO Technical Committee 276, which includes input from industry, regulatory, and academic stakeholders, the standard represents a global agreement to raise the bar.

Instead of prescribing a single method, the standard provides a framework for selecting and validating fit-for-purpose analytical techniques. It outlines key requirements for managing variability and ensuring that the chosen method provides a functionally relevant assessment of cellular health. For an industry grappling with scaling up production for more than 2,200 therapies currently in development, this common analytical framework is not just a guideline; it is a critical piece of infrastructure.

By creating a shared language and set of expectations for what constitutes a robust viability measurement, the standard aims to reduce process uncertainty, strengthen comparability between different manufacturing runs and sites, and increase confidence in the data submitted to regulatory bodies like the FDA and EMA. It is a move to transform cell manufacturing from a bespoke craft into a predictable, scalable science.

Seeing Cells in a New Light

Explicitly included within the new ISO guidance is an advanced analytical approach that moves far beyond the simple in-or-out logic of trypan blue. The technology, pioneered by Charlottesville-based LumaCyte, uses a combination of optical and fluidic forces to probe the intrinsic biochemical and biophysical properties of individual cells without the need for any labels or dyes.

This method, known as Laser Force Cytology (LFC), provides a multi-dimensional portrait of a cell’s health, or “vitality.” It can detect subtle changes in a cell’s internal structure and response that are early indicators of stress, activation, or decline—long before the cell membrane gives way. This allows for a more direct, reproducible, and functionally relevant assessment of the cellular state.

This is the second time this year the company’s technology has been written into a global ISO standard, following its inclusion in ISO 16921-2:2026 for viral vector quantification, another critical component of gene therapy. While measuring viral vectors is crucial, the assessment of mammalian cell viability is foundational to nearly all biologics and cell-based therapies, making the latest inclusion a broader and more fundamental development.

“This second ISO inclusion reflects the expanding role of advanced precision analytics in defining how cellular systems are measured and understood,” said Sean Hart, CEO and CSO of LumaCyte, in a statement. “Cell vitality is a foundational measurement across biologics and cell therapy, and improved insight into cell state has the potential to enhance how these therapies are developed and manufactured.”

From Bench to Bedside: The Patient Impact

While the language of ISO standards and biophysical analytics can seem esoteric, the implications are profoundly human. Every step that reduces variability and increases quality control in the manufacturing process is a step toward making cell therapies safer, more effective, and more reliable for patients.

Consistent, high-quality manufacturing is essential for expanding patient access. It underpins the ability to scale up production, which can help drive down the often-astronomical costs of these treatments. It also facilitates the efficient transfer of technology, allowing therapies developed in one lab to be produced reliably at manufacturing sites around the world. For the more than 60 new gene therapies expected to be approved by 2030, this level of standardization is not optional—it is essential for meeting patient demand.

By moving away from lagging indicators and embracing technologies that provide a real-time, functional understanding of the living ingredients in these therapies, the industry is taking a crucial step toward fulfilling its promise. This new standard is more than a technical document; it is a commitment to precision and accountability, ensuring that the revolutionary power of cell therapy is built on the strongest possible foundation.